Welcome!

News Feed Item

PDI Reports 2014 Second Quarter Financial Results

Management Will Host Conference Call Tomorrow August 14 at 8:30 am ET

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the second quarter ended June 30, 2014. Summary financial and operational accomplishments include:

  • Revenue of $31.6 million for the second quarter of 2014
  • Adjusted EBITDA (a non-GAAP financial measure) of $(1.5) million for the second quarter of 2014
  • On August 13, 2014, PDI acquired Asuragen, Inc.'s miRInform Thyroid and miRInform Pancreas cancer test assets
  • Subsequent to the second quarter, Heiner Dreismann, Ph.D., a highly experienced molecular diagnostics executive and former President and CEO of Roche Molecular Systems, joined PDI's board of directors
PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise.

 

 

Condensed Summary Statements of Continuing Operations (Unaudited)

($'s in thousands, expect per share data)










2nd Quarter Ended


Six Months Ended




June 30,*


June 30,*




2014


2013


2014


2013











Revenue, net


$           31.6


$           37.2


$           64.4


$           80.2











Gross profit


4.8


6.8


9.9


15.3











Operating expenses:









   Compensation expense

3.9


4.9


7.4


9.1

   Other SG&A


3.5


2.8


6.5


4.8

         Total operating expenses

7.3


7.7


13.9


13.9











Operating (loss) income 

$           (2.5)


$            (0.8)


$           (4.0)


$             1.4











Provision for income tax

0.1


0.1


0.1


0.1

(Loss) income from continuing operations

$           (2.6)


$            (0.9)


$           (4.2)


$             1.2











Diluted (loss) income per share from continuing operations

$         (0.17)


$          (0.06)


$         (0.28)


$           0.08

  *Unaudited









 

CEO Comments

"We are extremely excited to announce the agreement to acquire specific diagnostic assets from Asuragen, Inc. The transaction is the first step for our Interpace Diagnostic subsidiary in expanding into higher growth, higher margin markets and starts to establish Interpace as a commercially focused molecular diagnostic subsidiary," said Nancy Lurker, CEO.

"The transaction includes two oncology assays, miRInform Thyroid and miRInform Pancreas, associated intellectual property, a large biobank with over 5,000 patient tissue samples, as well as, additional thyroid tests in development."

"In addition, Heiner Dreismann, Ph.D., has joined our board of directors and brings with him nearly 30 years of experience in the diagnostic industry and extensive background in molecular diagnostics including his former tenure as President and CEO of Roche Molecular Systems. We look forward to his invaluable insight as we continue to evolve as a company."

"In terms of second quarter results, our revenue of $32 million were in line with our expectations and continues to reflect the soft RFP volume we experienced in our Sales Services business. Gross margins of 15%, while down compared to last year, are in line with current industry norms. Our adjusted EBITDA loss of $1.5 million in the quarter was primarily driven by spending on our key strategic initiatives and lower gross profit," said Nancy Lurker, CEO.

Ms. Lurker continued, "As for our outlook for the remainder of the year, we continue to expect revenue in our core business to be down in the third quarter and for the full year compared to 2013. We still anticipate an operating loss in the range of $4 - $5 million and approximately breakeven adjusted EBITDA in the core business for the full year 2014. Given today's Asuragen transaction, we now see a modest amount of revenues from Interpace Diagnostic for 2014 and an operating loss in the range of $5 - $6 million from all Interpace Diagnostics activities including additional selling and marketing and pre-launch expenses to support the anticipated ramp up of revenue from the acquired Asuragen assets."

Second Quarter Business Review

Revenue- For the second quarter of 2014, revenue of $31.6 million was $5.7 million or 15% lower than the second quarter of 2013 driven by the natural expiration or reduction of contracts being executed in 2014 exceeding new contracts entered into in the company's Sales Services segment.

  • Sales Services revenue of $28.1 million was $4.2 million lower than the second quarter of 2013. New contract wins from the softer RFP volume experienced in the latter half of 2013 was not sufficient to offset the natural expiration or reduction of certain contracts.

  • Marketing Services revenue of $0.6 million was $1.0 million lower than the second quarter of 2013 due to fewer contract signings by Group DCA.

  • Product Commercialization Services revenue of $2.9 million was $0.4 million lower than the second quarter of 2013.

Gross Profit- For the second quarter of 2014, gross profit of $4.8 million was $2.1 million lower than the second quarter of 2013 and, as anticipated, the overall gross profit percentage decreased to 15% in 2014 from 18% in 2013.

  • Sales Services gross profit of $4.8 million was $0.5 million lower than the second quarter of 2013 due primarily to lower revenue and previously disclosed competitive pricing pressures.

  • Marketing Services gross profit for the second quarter of 2014 was a negative $0.5 million due to the decrease in revenue and increased costs associated with the launch of our new product, PD One.

  • Product Commercialization Services gross profit of $0.6 million was $0.4 million lower compared to the second quarter of 2013 primarily due to expenses related to one of our collaboration agreements for molecular diagnostic tests.

Total Operating Expenses- Total operating expenses for the second quarter of 2014 were $7.3 million as compared to $7.7 million for the same period in 2013. Included in second quarter 2014 expenses are $0.7 million of investment costs related to our molecular diagnostics strategic initiative. Excluding these costs, total operating expenses for the second quarter of 2014 were $6.6 million; $1.1 million lower than 2013 operating expenses.

Operating Income/Loss- The operating loss for the second quarter of 2014 was $2.5 million, compared to $0.8 million for the same period in 2013.  The 2014 operating loss was primarily the result of the anticipated lower revenue and margins as well as the company's investment in strategic initiatives.

Liquidity and Cash Flow- Adjusted EBITDA (a non-GAAP measure defined in the release) for the second quarter of 2014 was $(1.5) million compared to $0.2 million in the second quarter of 2013. Cash and cash equivalents at the end of the second quarter were $35.6 million, down $10.0 million from December 31, 2013 due primarily to increases in working capital requirements, timing of certain payments from customers and investments in our strategic initiatives. Factoring in the Asuragen acquisition and anticipated additional spending in Interpace Diagnostics, the company estimates year end 2014 cash of $22 - $25 million.

As of June 30, 2014, the company's cash equivalents were predominantly invested in U.S. Treasury money market funds and the company had no commercial debt.

Non-GAAP Financial Measures

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, PDI has provided a certain non-GAAP financial measure to help evaluate the results of its performance. The company believes that this non-GAAP financial measure, when presented in conjunction with comparable GAAP financial measure, is useful to both management and investors in analyzing the company's ongoing business and operating performance. The company believes that providing non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the company's financial results in the way that management views financial results.

In this document, the company discusses Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as operating income or loss, plus depreciation and amortization, non-cash stock-based compensation, and other non-cash expenses. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

Adjusted EBITDA (Unaudited)

($ in thousands)




2nd Quarter Ended


Six Months Ended




June 30,


June 30,




2014


2013


2014


2013











Operating (loss) income 

$       (2,523)


$           (847)


$       (4,020)


$         1,406

Depreciation and amortization

380


289


837


577

Stock compensation


668


722


1,358


1,073

Adjusted EBITDA


$       (1,475)


$            164


$       (1,825)


$         3,056

 

Conference Call

As previously announced, PDI will hold a conference call Thursday, August 14, 2014 to discuss financial and operational results of the second quarter ended June 30, 2014.  Details as follows:

Time: 8:30 AM (ET)
Dial-in numbers: (855) 592-8761 (U.S. and Canada) or (724) 924-4975
Conference ID#: 27904432

Live webcast: www.pdi-inc.com, under "Investor Relations"

The teleconference replay will be available three hours after completion through September 13, 2014 at (855) 859-2056 (U.S. and Canada) or (404) 537-3406. The replay pass code is 27904432. The archived web cast will be available for one year.

About PDI, Inc.

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. PDI's Interpace Diagnostics division is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company's Contract Sales business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. Its Group DCA division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery.

For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdi-inc.com and www.interpacediagnostics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers or the inability to secure additional business. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's previously filed Annual Report on Form 10-K for the year ended December 31, 2013 and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

PDI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(in thousands, except per share data)










Three Months Ended


Six Months Ended


June 30,


June 30,


2014


2013


2014


2013









Revenue, net

$         31,578


$         37,245


$      64,356


$        80,168

Cost of services

26,787


30,396


54,456


64,846

Gross profit

4,791


6,849


9,900


15,322









Compensation expense

3,862


4,914


7,403


9,069

Other selling, general and administrative expenses

3,452


2,782


6,517


4,847

Total operating expenses

7,314


7,696


13,920


13,916

Operating (loss) income 

(2,523)


(847)


(4,020)


1,406

Other expense, net

(13)


(24)


(30)


(34)

(Loss) income from continuing operations before








income tax

(2,536)


(871)


(4,050)


1,372

Provision for income tax

65


64


131


128

(Loss) income from continuing operations

(2,601)


(935)


(4,181)


1,244

(Loss) income  from discontinued operations, net of tax

(57)


52


(89)


(2)









Net (loss) income 

$          (2,658)


$             (883)


$       (4,270)


$          1,242









Basic (loss) income per share of common stock:








From continuing operations

$            (0.17)


$            (0.06)


$         (0.28)


$             0.08

From discontinued operations

(0.01)


-


(0.01)


-

Net (loss) income per basic share of common stock

$            (0.18)


$            (0.06)


$         (0.29)


$             0.08









Diluted (loss) income per share of common stock:








From continuing operations

$            (0.17)


$            (0.06)


$         (0.28)


$             0.08

From discontinued operations

(0.01)


-


(0.01)


-

Net (loss) income per diluted share of common stock

$            (0.18)


$            (0.06)


$         (0.29)


$             0.08









Weighted average number of common shares and








common share equivalents outstanding:








Basic

14,910


14,713


14,860


14,691

Diluted

14,910


14,713


14,860


15,154

 

Segment Data (Unaudited)

($ in thousands)










Sales


Marketing


PC



Services


Services


Services*


Consolidated

Three months ended June 30, 2014:








Revenue, net

$         28,067


$              614


$        2,897


$        31,578

Gross profit (loss)

$           4,765


$            (526)


$           552


$          4,791

Gross profit %

17.0%


-85.7%


19.1%


15.2%









Three months ended June 30, 2013:








Revenue, net

$         32,294


$           1,644


$        3,307


$        37,245

Gross profit

$           5,252


$              638


$           959


$          6,849

Gross profit %

16.3%


38.8%


29.0%


18.4%










Sales


Marketing


PC



Services


Services


Services*


Consolidated

Six months ended June 30, 2014:








Revenue, net

$         56,862


$          1,617


$        5,877


$        64,356

Gross profit (loss)

$           9,508


$            (694)


$        1,086


$          9,900

Gross profit %

16.7%


-42.9%


18.5%


15.4%









Six months ended June 30, 2013:








Revenue, net

$         70,519


$          3,185


$        6,464


$        80,168

Gross profit

$         12,571


$          1,022


$        1,729


$        15,322

Gross profit %

17.8%


32.1%


26.7%


19.1%









* Product Commercialization (PC) Services



 

 

Selected Balance Sheet Data (Unaudited)

($ in thousands)


 June 30, 


 December 31, 


2014


2013





Cash and cash equivalents

$         35,621


$         45,639





Total current assets

$         53,176


$         62,709

Total current liabilities

25,621


31,400

Working capital

$         27,555


$         31,309





Total assets

$         59,459


$         69,064

Total liabilities

$         30,107


$         36,585

Total stockholders' equity

$         29,352


$         32,479









Selected Cash Flow Data (Unaudited)

($ in thousands)


June 30,


2014


2013





Net (loss) income

$       (4,270)


$        1,242

Non-cash items:




     Depreciation and amortization

837


577

     Stock-based compensation

1,358


1,073

     Other

71


71

Net change in assets and liabilities

(6,284)


(3,537)

Net cash used in operations

$       (8,288)


$         (574)





Change in cash and cash equivalents

$     (10,018)


$      (1,760)

Logo - http://photos.prnewswire.com/prnh/20140114/NY45872LOGO

SOURCE PDI, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business in 2016. However, IoT is far more complex than most firms expected. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, a renowned visionary and thought leader, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology and business models to adopt and leverage IoT. He will drill down to the components in this fra...
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
The vision of a connected smart home is becoming reality with the application of integrated wireless technologies in devices and appliances. The use of standardized and TCP/IP networked wireless technologies in line-powered and battery operated sensors and controls has led to the adoption of radios in the 2.4GHz band, including Wi-Fi, BT/BLE and 802.15.4 applied ZigBee and Thread. This is driving the need for robust wireless coexistence for multiple radios to ensure throughput performance and th...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Big Data at Cloud Expo - to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is...
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the protocols that communicate data and the emerging data analy...